Pfizer says it could be leader in cancer with many new drugs

  • By Linda A. Johnson Associated Press
  • Tuesday, September 22, 2015 1:42pm
  • Business

Drug giant Pfizer is starting 20 clinical trials this year and more soon after on treatments to conquer cancer as it also seeks to gain leadership in one of the hottest, and most lucrative, areas of medicine.

A decade ago, the world’s second-biggest drugmaker by revenue wasn’t even a player in cancer medicine. Instead, it was known for erectile dysfunction treatment Viagra and blockbuster cholesterol fighter Lipitor.

New York-based Pfizer Inc. then chose to make cancer one of its core research areas, pitting it against cancer powerhouses including Novartis AG, Roche Holding AG, Bristol-Myers Squibb Co. and Merck &Co.

Today, Pfizer has eight approved cancer medicines, four of them launched in the last four years. It’s running late-stage patient tests on five of those drugs for additional uses, has three other drugs in late-stage testing — usually the last round before seeking regulators’ approval — and has 14 other drug programs in early stages.

Those programs together provide for a two-pronged attack on cancer, including tumor-killing drugs and treatments in the promising new class called immuno-oncology that stimulate the immune system to mount a stronger defense against cancer.

Scientists “have never been closer to finding a cancer cure,” Mikael Dolsten, Pfizer’s head of worldwide research and development, told journalists Tuesday during an update on the company’s cancer research strategy.

“Compared to other companies, we are uniquely positioned to be a leader” in cancer, Dolsten added.

He and other Pfizer executives said that’s because killing tumors and preventing cancer recurrence requires regimens of multiple drugs given together or sequentially, and the company has many drugs that work by different mechanisms to try together.

“They clearly have the scale and R&D experience over time to be a major player in the immuno-oncology market,” said Edward Jones analyst Ashtyn Evans. “We’ve seen them do a lot in a short time.”

“They’re still pretty far behind Merck and Bristol in immuno-oncology,” she added, “but it’s going to be a large market that will have room for multiple players.”

Evans said Pfizer’s best prospect is its newest drug, breast cancer medicine Ibrance, now being tested against multiple other cancers. She thinks by 2020 Pfizer could boost its cancer drug sales to about 10 percent of revenue, up from barely 4 percent of its $50 billion in annual revenue now.

Asked about the high prices for cancer medicines, given that patients receive multiple treatments, Liz Barrett, head of cancer drug marketing, told reporters Pfizer will be looking at pricing for combinations of its drugs and noted the company gives away billions of dollars of its medicines.

Patients and insurance plans increasingly are raising alarms about prices of around $100,000 a year for new drugs for cancer and some other conditions, plus recent huge price hikes for some old drugs. Now Democratic presidential candidates Hillary Clinton and Bernie Sanders, the Vermont senator, have made them campaign issues with proposals to let Americans buy cheaper drugs overseas, bring the federal government bigger discounts on drugs it buys and even make insurance plans cap what patients pay for their medication.

Pfizer’s scientists now are collaborating more internally and have numerous partnerships with university researchers uncovering scientific insights and with other pharmaceutical and biotech companies, said Mace Rothenberg, a senior vice president who oversees Pfizer’s efforts to discover potential cancer treatments.

Those partnerships range from one with iTeos Therapeutics giving Pfizer rights to two compounds in laboratory testing to one testing rival Merck’s immuno-oncology drug Keytruda with two approved Pfizer drugs and an experimental one.

Dolsten and other Pfizer executives said the key to better treatments is putting together the best targeted drug combinations and, before testing them in people, seeing how well they work on animals manipulated to have tumors with the same genetic variations as the patients they’re hoping to help.

Pfizer’s cancer research programs include ones using six different types of technology to target tumor cells, from genetically engineered antibodies to therapeutic vaccines, which use patients’ own tumor cells to create vaccines personalized to the genetic characteristics of their cancer.

Some of those programs are creating pills and antibody-based injected drugs that fight tumors by attacking “networks” within them that involve tumor metabolism, signaling and changes in gene function caused by external factors.

Pfizer also is developing several immuno-oncology treatments, including pills, injected drugs and therapeutic vaccines. Pfizer already has five such compounds in patient testing and expects to start testing in another five next year.

Talk to us

> Give us your news tips.

> Send us a letter to the editor.

> More Herald contact information.

More in Business

Black Press Media operates Sound Publishing, the largest community news organization in Washington State with dailies and community news outlets in Alaska.
Black Press Media concludes transition of ownership

Black Press Media, which operates Sound Publishing, completed its sale Monday (March 25), following the formerly announced corporate restructuring.

Maygen Hetherington, executive director of the Historic Downtown Snohomish Association, laughs during an interview in her office on Thursday, Feb. 15, 2024, in Snohomish, Washington. (Ryan Berry / The Herald)
Maygen Hetherington: tireless advocate for the city of Snohomish

Historic Downtown Snohomish Association receives the Opportunity Lives Here award from Economic Alliance.

FILE - Washington Secretary of State Steve Hobbs poses in front of photos of the 15 people who previously held the office on Nov. 22, 2021, after he was sworn in at the Capitol in Olympia, Wash. Hobbs faces several challengers as he runs for election to the office he was appointed to last fall. (AP Photo/Ted S. Warren, File)
Secretary of State Steve Hobbs: ‘I wanted to serve my country’

Hobbs, a former Lake Stevens senator, is the recipient of the Henry M. Jackson Award from Economic Alliance Snohomish County.

Mark Duffy poses for a photo in his office at the Mountain Pacific Bank headquarters on Wednesday, Feb. 14, 2024 in Everett, Washington. (Annie Barker / The Herald)
Mark Duffy: Building a hometown bank; giving kids an opportunity

Mountain Pacific Bank’s founder is the recipient of the Fluke Award from Economic Alliance Snohomish County.

Barb Tolbert poses for a photo at Silver Scoop Ice Cream on Thursday, Feb. 29, 2024 in Arlington, Washington. (Annie Barker / The Herald)
Barb Tolbert: Former mayor piloted Arlington out of economic brink

Tolbert won the Elson S. Floyd Award, honoring a leader who has “created lasting opportunities” for the underserved.

Photo provided by 
Economic Alliance
Economic Alliance presented one of the Washington Rising Stem Awards to Katie Larios, a senior at Mountlake Terrace High School.
Mountlake Terrace High School senior wins state STEM award

Katie Larios was honored at an Economic Alliance gathering: “A champion for other young women of color in STEM.”

The Westwood Rainier is one of the seven ships in the Westwood line. The ships serve ports in the Pacific Northwest and Northeast Asia. (Photo provided by Swire Shipping)
Westwood Shipping Lines, an Everett mainstay, has new name

The four green-hulled Westwood vessels will keep their names, but the ships will display the Swire Shipping flag.

A Keyport ship docked at Lake Union in Seattle in June 2018. The ship spends most of the year in Alaska harvesting Golden King crab in the Bering Sea. During the summer it ties up for maintenance and repairs at Lake Union. (Keyport LLC)
In crabbers’ turbulent moment, Edmonds seafood processor ‘saved our season’

When a processing plant in Alaska closed, Edmonds-based business Keyport stepped up to solve a “no-win situation.”

Angela Harris, Executive Director of the Port of Edmonds, stands at the port’s marina on Wednesday, Jan. 24, 2024, in Edmonds, Washington. (Ryan Berry / The Herald)
Leadership, love for the Port of Edmonds got exec the job

Shoring up an aging seawall is the first order of business for Angela Harris, the first woman to lead the Edmonds port.

The Cascade Warbirds fly over Naval Station Everett. (Sue Misao / The Herald file)
Bothell High School senior awarded $2,500 to keep on flying

Cascade Warbirds scholarship helps students 16-21 continue flight training and earn a private pilot’s certificate.

Rachel Gardner, the owner of Musicology Co., a new music boutique record store on Thursday, Jan. 18, 2024 in Edmonds, Washington. Musicology Co. will open in February, selling used and new vinyl, CDs and other music-related merchandise. (Olivia Vanni / The Herald)
New Edmonds record shop intends to be a ‘destination for every musician’

Rachel Gardner opened Musicology Co. this month, filling a record store gap in Edmonds.

MyMyToyStore.com owner Tom Harrison at his brick and mortar storefront on Tuesday, Sept. 6, 2022 in Everett, Washington. (Olivia Vanni / The Herald)
Burst pipe permanently closes downtown Everett toy store

After a pipe flooded the store, MyMyToystore in downtown Everett closed. Owner Tom Harrison is already on to his next venture.

Support local journalism

If you value local news, make a gift now to support the trusted journalism you get in The Daily Herald. Donations processed in this system are not tax deductible.